CGC · Canopy Growth Corp
The latest filing no longer states the doubt (first flagged Jun 15, 2026).
View the 10-Q filed Aug 7, 2026Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Dec 20, 2023; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted gross margin non-GAAP | 31% | Q1 FY2027 | — |
| Adjusted EBITDA loss non-GAAP | CAD 20.2M | FY2026 | — |
| Free cash outflow non-GAAP | CAD 69.1M | FY2026 | — |
| Net cash position non-GAAP | CAD 131.3M | FY2026 | — |
| Annualized savings | CAD 29M | FY2026 year-to-date | — |
| Cannabis gross margin | 25% | Q3 FY2026 | — |
| Consolidated gross margin | 29% | Q3 FY2026 | — |
| Free cash flow non-GAAP | -CAD 19M | Q3 FY2026 | — |
| Storz & Bickel gross margin | 37% | Q3 FY2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGC
this stock
Canopy Growth Corp
|
$431.50M | -10.5% | — | — | 5.9% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$55.60B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.59B | +2.4% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.81B | +17.8% | +4.3% | 60.2 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Dec 20, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGC | +5.2% | +8.5% | -11.3% | +11.2% | -10.5% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +4.8% | +4.1% | -25.1% | +7.3% | -24.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.